Real-time tracking of pharmaceutical manufacturing volume would go a long way toward helping the US Food and Drug Administration better anticipate drug shortages and drug-related national security risks, Janet Woodcock, director of the agency’s Center for Drug Evaluation and Research, told Congress 30 October.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?